AT1 receptors in atherosclerosis: Biological effect including growth, angiogenesis, and apoptosis

European Heart Journal, Supplement

Volumn 5, Issue A, 2003, Pages

  Werner, N ^a   Nickenig, G ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Angiogenesis; Angiotensin II; Apoptosis; AT1 receptor; Atherosclerosis; Reactive oxygen species

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; REACTIVE OXYGEN METABOLITE;

ANGIOGENESIS; APOPTOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL GROWTH; CONFERENCE PAPER; ENDOTHELIUM CELL; ENDOTHELIUM LESION; HEART INFARCTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR SMOOTH MUSCLE;

EID: 0037251184     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(03)90058-7     Document Type: Conference Paper

References (53)

1. Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev 1977; 57: 313-70.
2. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation 1993; 87: 1816-28.
3. Timmermans PB, Wong PC, Chiu AT et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-51.
4. Griendling KK, Lassègue B, Alexander RW. Angiotensin receptors and their therapeutic implications. Annu Rev Pharmacol Toxicol 1996; 36: 281-306.
5. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999; 340, 2: 115-26.
6. 1 receptor blockade and atherosclerosis: hopeful insights into vascular protection. Circulation 2000; 101: 1496-7.
7. Strawn WB, Dean RH, Ferrario CM. Novel mechanisms linking angiotensin II and early atherogenesis. JRAAS 2000; 1: 11-7.
8. Mallat Z, Tedgui A. Apoptosis in the vasculature: mechanisms and functional importance. Br J Pharmacol 2000; 130: 947-62.
9. Lemay J, Hamet P, deBlois D. Losartan-induced apoptosis as a novel mechanism for the prevention of vascular lesion formation after injury. JRAAS 2000; 1: 46-50.
10. Dzau VJ. Mechanism of protective effects of ACE inhibition on coronary artery disease. Eur Heart J 1998; 19 Suppl J: J2-6.
11. Romero JC, Reckelhoff JF. State-of-the-Art lecture. Role of angiotensin and oxidative stress in essential hypertension. Hypertension 1999; 34: 943-9.
12. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NAD(P)H oxidase activity in cultured smooth muscle cells. Circ Res 1994; 74: 1141-8.
13. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
14. Suh YA, Arnold RS, Lassègue B et al. Cell transformation by the superoxide-generating oxidase Mox 1. Nature 1999; 401: 79-82.
15. Meyer JW, Schmitt ME. A central role for the endothelial NAD(P)H oxidase in atherosclerosis. FEBS Lett 2000; 472: 1-4.
16. Griendling KK, Sorescu D, Lassègue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000; 20: 2175-83.
17. Wassmann S, Laufs U, Bäumer AT et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac 1 GTPase. Mol Pharmacol 2001; 59: 646-54.
18. Hsieh HJ, Cheng CC, Wu ST, Chiu JJ, Wung BS, Wang DI. Increase of reactive oxygen species (ROS) in endothelial cells by shear flow and involvement of ROS in shear-induced c-fos expression. J Cell Physiol 1998; 175: 156-62.
19. Abe J, Berk BC. Fyn and JAK2 mediate Ras activation by reactive oxygen species. J Biol Chem, 1999; 274: 21003-10.
20. Kawakami M, Okabe E. Superoxide anion radical-triggered Ca2+ release from cardiac sarcoplasmic reticulum through ryanodine receptor Ca 2+ channel. Mol Pharmacol 1998; 53: 497-503.
21. Ushio-Fukai M, Alexander RW, Akers M, Griendling KK. p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. J Biol Chem 1998; 273: 15022-9.
22. Ushio-Fukai M, Alexander RW, Akers M et al. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem 1999; 274: 22699-704.
23. Harrison DG. Endothelial function and oxidant stress. Clin Cardiol 1997; 20: II-11-7.
24. Patel RP, Moellering D, Murphy-Ullrich J, Jo H, Beckmann JS, Darley-Usmar VM. Cell signaling by reactive nitrogen and oxygen species in atherosclerosis. Free Radic Biol Med 2000; 28: 1780-94.
25. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000; 20: 645-51.
26. Usui M, Egashira K, Tomita H et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 2000; 101: 305-10.
27. Luft FC, Mervaala E, Muller DN et al. Hypertension-induced end-organ damage. A new transgenic approach to an old problem. Hypertension 1999; 33: 212-8.
28. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997; 95: 588-93.
29. Mancini GB, Henry GC, Macaya C et al. Angiotensin converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996; 94: 258-65.
30. Prasad A, Tupas-Habib T, Schenke WH et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000; 101: 2349-54.
31. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-59.
32. Kranzhöfer R, Browatzki M, Schmidt J, Kübler W. Angiotensin II activates the proinflammatory transcription factor nuclear factorkappa B in human monocytes. Biochem Biophys Res Commun 1999; 257: 826-8.
33. Morawietz H, Rueckschloss U, Niemann B et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized lowdensity lipoprotein. Circulation 1999; 100: 899-902.
34. Keidar S, Attias J. Angiotensin II injection into mice increases the uptake of oxidized LDL by their macrophages via a proteoglycanmediated pathway. Biochem Biophys Res Commun 1997; 239: 63-7.
35. Schieffer B, Schieffer E, Hilfiker-Kleiner D et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000; 101: 1372-8.
36. Funck RC, Wilke A, Rupp H, Brilla CG. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv Exp Med Biol 1997; 432: 35-44.
37. Müller C, Baudler S, Welzel H, Böhm M, Nickenig G. Identification of a novel redox-sensitive gene, Id3, which mediates angiotensin II-induced cell growth. Circulation 2002; 105: 2423-8.
38. Bennett MR, Evan GI, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest 1995; 95: 2266-74.
39. Kockx MM. Apoptosis in the atherosclerotic plaque: quantitative and qualitative aspects. Arterioscler Thromb Vasc Biol 1998; 18: 1519-22.
40. Mallat Z, Tedgui A. Current perspective on the role of apoptosis in atherothrombotic disease. Circ Res 2001; 88: 998-1003.
41. Bonnet F, Cao Z, Cooper ME. Apoptosis and angiotensin II: yet another renal regulatory system? Exp Nephrol 2001; 9: 295-300.
42. Li D, Yang B, Philips MI, Mehta JL. Proapoptotic effects of ANG II in human coronary artery endothelial cells: role of AT1-receptor and PKC activation. Am J Physiol 1999; 276: H786-92.
43. Diep QN, Li JS, Schiffrin EL. In vivo study of AT1 and AT2 angiotensin receptors in apoptosis in rat blood vessels. Hypertension 1999; 34: 617-24.
44. Hayden MR, Tyagi SC. Arteriogenesis: Angiogenesis within unstable atherosclerotic plaque-interactions with extracellular matrix. Curr Interv Cardiol Rep 2000; 2: 218-27.
45. Fujiyama S, Matsubara H, Nozawa Y et al. Angiotensin AT1 and AT2 receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding - epidermal growth factor (EGF) - mediated EGF receptor transactivation. Circ Res 2001; 88: 22-9.
46. Tamarat R, Silvestre JS, Kubis N et al. Endothelial nitric oxide synthase lies downstream from angiotensin II-induced angiogenesis in ischemic hindlimb. Hypertension 2002; 39: 830-5.
47. Emanueli C, Salis MB, Stacca T, Pinna A, Gaspa L, Maddeddu P. Angiotensin AT1 receptor signalling modulates reparative angiogenesis induced by limb ischaemia. Br J Pharmacol 2002; 135: 87-92.
48. Sasaki K, Murohara T, Ikeda H et al. Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J Clin Invest 2002; 109: 603-11.
49. Yoshiji H, Kuriyama S, Kawata M et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: Possible role of the vascular endothelial growth factor. Clin Cancer Res 2001; 7(4): 1073-8.
50. Pitt B. The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia. Am J Cardiol 1997; 79(5A): 24-8.
51. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8.
52. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
53. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, for the Heart Outcome Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.